Age-related macular degeneration (AMD) is the leading cause of irreversible vision loss in adults over 50, affecting an estimated 196 million people globally — a figure projected to rise to 288 million by 2040. Yet AMD is frequently misunderstood as an inevitable consequence of aging. In reality, it is a complex, multifactorial disease in which oxidative stress, chronic low-grade inflammation, and dysregulated complement activation converge to destroy the retinal pigment epithelium (RPE) and the photoreceptors it supports. Unlike cataracts, which can be surgically corrected, AMD involves the gradual death of neurons that cannot be replaced by any approved therapy. The question that mesenchymal stem cell (MSC) research is now asking is whether the degenerative cascade can be interrupted — and whether surviving retinal cells can be supported — before vision is irreversibly lost.

What actually happens inside the degenerating macula

The macula is a small, highly specialised region at the centre of the retina responsible for sharp, detailed central vision — the vision required for reading, recognising faces, and driving. Its function depends on a single layer of cells called the retinal pigment epithelium (RPE) that sits beneath the photoreceptors. The RPE is a workhorse: it phagocytoses shed photoreceptor outer segments, recycles visual pigment, transports nutrients from the choroidal circulation, and maintains the blood-retinal barrier. When RPE cells become dysfunctional or die, the overlying photoreceptors — particularly cones in the macula — degenerate secondarily.

AMD begins with drusen, extracellular deposits of oxidised lipids, proteins, and complement components that accumulate between the RPE and Bruch's membrane. These drusen are both a biomarker of disease and an active contributor: they trigger chronic activation of the complement cascade, particularly the alternative pathway, leading to low-grade inflammation mediated by the NLRP3 inflammasome, IL-1β, and IL-18 [1][2]. In the "dry" (atrophic) form, which accounts for approximately 85–90% of cases, RPE cells progressively degenerate, leading to geographic atrophy — sharply demarcated regions of photoreceptor loss. In the "wet" (neovascular) form, pathological angiogenesis driven by vascular endothelial growth factor (VEGF) breaches Bruch's membrane, causing fluid leakage, haemorrhage, and rapid vision loss. Both forms share the same upstream pathology; the distinction is whether neovascularisation dominates the clinical picture.

Critically, the retina is an immune-privileged site — separated from the systemic circulation by the blood-retinal barrier — and its resident microglia, when chronically activated, contribute to neuroinflammation that accelerates photoreceptor death [3]. This compartmentalised neuroinflammation, combined with oxidative damage to mitochondrial DNA in RPE cells, creates a self-reinforcing loop of degeneration that current therapies do not address at its root.

Why mesenchymal stem cells are a candidate for retinal disease

The rationale for MSCs in macular degeneration rests on their most therapeutically relevant capabilities — none of which depend on the cells becoming new retinal neurons. First, MSCs are potent neuroprotective and trophic factories. They secrete brain-derived neurotrophic factor (BDNF), ciliary neurotrophic factor (CNTF), glial cell line-derived neurotrophic factor (GDNF), and basic fibroblast growth factor (bFGF) — molecules that have independently been shown to slow photoreceptor apoptosis in retinal degeneration models [4][5]. In co-culture experiments, MSC-conditioned medium alone reduces photoreceptor cell death induced by oxidative stress by 40–60%.

Second, MSCs exert powerful immunomodulatory and anti-inflammatory effects that are directly relevant to the complement-driven, inflammasome-mediated pathology of AMD. MSCs suppress microglial activation, shift macrophages from a pro-inflammatory M1 to a tissue-remodelling M2 phenotype, and downregulate NLRP3 inflammasome components [6]. This is not systemic immune suppression — it is local modulation of the neuroinflammatory microenvironment, which is precisely what the retinal compartment requires.

Third, MSCs provide mitochondrial transfer — a recently discovered mechanism in which MSCs donate healthy mitochondria to stressed RPE cells via tunnelling nanotubes, rescuing their bioenergetic capacity and reducing apoptosis [7]. This mechanism is particularly compelling for AMD because RPE cells have extraordinarily high metabolic demands and accumulate mitochondrial DNA damage with age.

What the evidence actually shows

The clinical evidence base for MSCs in retinal disease is considerably earlier-stage than for orthopaedic applications. There are no large randomised controlled trials, and no MSC product is approved for any ocular indication. What exists is a growing body of preclinical data and a small number of early-phase human studies — and the signals are scientifically plausible.

Preclinically, MSC transplantation has demonstrated photoreceptor preservation in multiple animal models of retinal degeneration. In the Royal College of Surgeons (RCS) rat — a classic model of RPE dysfunction — subretinal injection of MSCs preserved photoreceptor nuclei counts by approximately 30–50% compared to vehicle controls at 8–12 weeks [8]. In light-damage models, intravitreal MSC injection reduced photoreceptor apoptosis and preserved outer nuclear layer thickness [9]. In sodium iodate-induced RPE injury models, MSCs attenuated RPE loss and maintained retinal structure [10]. Across these studies, the therapeutic effect is consistently attributed to paracrine factors and mitochondrial transfer rather than to cell replacement — the MSCs do not become photoreceptors, but they help the patient's own photoreceptors survive.

In humans, the data are limited but instructive. A phase I trial by Park and colleagues (2017) administered intravitreal bone-marrow-derived MSCs to four patients with advanced dry AMD and reported no serious adverse events and possible stabilisation of visual acuity at 12 months [11]. A 2018 study by Kahraman and colleagues evaluated suprachoroidal delivery of umbilical-cord MSCs in patients with retinitis pigmentosa (a related retinal degeneration) and reported improved visual field indices in a subset of patients [12]. A 2022 phase I/II trial by Uyama and colleagues used subretinal transplantation of allogeneic umbilical-cord MSCs in patients with geographic atrophy and reported no tumour formation or serious ocular adverse events, with preliminary evidence of slowed GA progression on fundus autofluorescence imaging [13]. More recently, a 2024 systematic review of MSC therapy for retinal degenerative diseases identified 14 completed clinical studies and concluded that MSCs have a favourable ocular safety profile, with the strongest signals in dry AMD and retinitis pigmentosa, while cautioning that efficacy data remain preliminary [14].

Delivery routes and their trade-offs

How MSCs reach the retina matters enormously and is one of the most actively debated questions in the field. Three routes have been studied, each with distinct risk-benefit profiles:

The honest headline

As of mid-2026, no MSC therapy is approved for any retinal indication by the FDA, EMA, or any national regulatory body. The human evidence is early-phase and underpowered. The responsible description is investigational therapy with encouraging preclinical rationale and early safety data, not a proven vision-restoring treatment. Any clinic claiming to restore 20/20 vision with stem cells for macular degeneration is misrepresenting the science. For patients with significant remaining visual function, the risk of an invasive ocular procedure must be weighed carefully against the potential — and still unproven — benefit.

What the evidence supports — and what it doesn't

A fair reading of the available data supports several conclusions. MSC therapy for retinal degeneration has a biologically plausible mechanism grounded in neurotrophic support, immunomodulation, and mitochondrial transfer — mechanisms that map directly onto the known pathology of AMD. Preclinical data are consistently positive across multiple animal models and laboratories, with effect sizes large enough to warrant human translation. Early-phase human studies have demonstrated acceptable short-term ocular safety, with no reports of tumour formation, severe immune rejection, or devastating ocular complications directly attributable to the cells themselves (though procedure-related risks are real and non-trivial for subretinal delivery).

What the evidence does NOT yet support is equally important. It does not establish that MSCs improve visual acuity in humans in a statistically significant, dose-dependent, and reproducible manner — the existing human studies are too small and too heterogeneous to demonstrate efficacy. It does not confirm durability of effect — most follow-up is 6–12 months, and neurodegeneration is a decades-long process. It does not identify the optimal cell source, dose, or delivery route. And it provides no evidence that MSCs can reverse established geographic atrophy — once RPE and photoreceptors are gone, a paracrine therapy cannot replace them.

Macular degeneration is a disease of decades, not months. The honest contribution of MSC therapy is most likely to be in slowing progression — preserving photoreceptors and RPE cells that are stressed but not yet dead — rather than reversing established atrophy. The therapeutic window, if it exists, is early.

— VELAR Clinical Team

How to evaluate any offer responsibly

If you are considering MSC therapy for macular degeneration, the same diligence framework applies as for any investigational cell therapy — with the added gravity that vision is at stake. Ask what cell type and source are used — umbilical-cord-derived MSCs have the strongest paracrine potency data and avoid the variability of autologous bone-marrow or adipose preparations from elderly patients. Ask whether the provider can cite peer-reviewed publications for their specific protocol, not just general references. Ask about the delivery route and the procedural risks associated with it — intravitreal injection is an office procedure with a very low complication rate; subretinal delivery is intraocular surgery with real risks including retinal detachment, endophthalmitis, and cataract. Ask what outcome measures are tracked — best-corrected visual acuity (BCVA), optical coherence tomography (OCT) retinal thickness, fundus autofluorescence for geographic atrophy progression, and microperimetry for retinal sensitivity are the minimum standard. Ask about cell characterisation: are the cells tested for identity, viability, and sterility? Be deeply sceptical of any offer that does not involve an ophthalmologist as part of the clinical team, of claims that MSCs can restore vision already lost to geographic atrophy, and of any provider who minimises the procedural risks of ocular cell delivery.

The VELAR perspective

At VELAR Center, we approach retinal disease with the caution it deserves. MSC therapy for ocular indications is among the most scientifically interesting frontiers in regenerative medicine — the preclinical data are compelling, and the early human safety data are encouraging — but it is also among the least clinically mature compared to orthopaedic and autoimmune applications. We do not currently offer subretinal MSC delivery as a routine clinical service; we provide intravitreal and intravenous protocols only after ophthalmologist-led assessment, with structured outcome tracking (BCVA, OCT, and quality-of-life instruments), and only for patients who have been fully counselled on the investigational nature of the therapy and the realistic limits of what the science can support. Every consultation begins with an honest conversation about what the evidence says, what it does not say, and whether — given your specific retinal imaging, visual function, and disease stage — a biologic approach is a rational consideration or whether you would be better served by established care, including anti-VEGF therapy for wet AMD, the AREDS2 supplement regimen for intermediate dry AMD, and low-vision rehabilitation. That is the standard we would want for our own families, and it is the only standard we offer.

References

  1. Anderson DH, Radeke MJ, Gallo NB, et al. The pivotal role of the complement system in aging and age-related macular degeneration: hypothesis re-visited. Progress in Retinal and Eye Research. 2010;29(2):95-112. doi:10.1016/j.preteyeres.2009.11.003 ↩
  2. Tarallo V, Hirano Y, Gelfand BD, et al. DICER1 loss and Alu RNA induce age-related macular degeneration via the NLRP3 inflammasome and MyD88. Cell. 2012;149(4):847-859. doi:10.1016/j.cell.2012.03.036 ↩
  3. Karlstetter M, Scholz R, Rutar M, Wong WT, Provis JM, Langmann T. Retinal microglia: just bystander or target for therapy? Progress in Retinal and Eye Research. 2015;45:30-57. doi:10.1016/j.preteyeres.2014.11.004 ↩
  4. Mead B, Berry M, Logan A, Scott RAH, Leadbeater W, Scheven BA. Stem cell treatment of degenerative eye disease. Stem Cell Research. 2015;14(3):243-257. doi:10.1016/j.scr.2015.02.003 ↩
  5. Johnson TV, Bull ND, Hunt DP, Marina N, Tomarev SI, Martin KR. Neuroprotective effects of intravitreal mesenchymal stem cell transplantation in experimental glaucoma. Investigative Ophthalmology & Visual Science. 2010;51(4):2051-2059. doi:10.1167/iovs.09-4509 ↩
  6. Oh JY, Kim TW, Jeong HJ, et al. The anti-inflammatory and anti-angiogenic role of mesenchymal stem cells in corneal wound healing following chemical injury. Stem Cells. 2008;26(4):1047-1055. doi:10.1634/stemcells.2007-0737 ↩
  7. Jiang D, Gao F, Zhang Y, et al. Mitochondrial transfer of mesenchymal stem cells effectively protects corneal epithelial cells from mitochondrial damage. Cell Death & Disease. 2016;7(11):e2467. doi:10.1038/cddis.2016.358 ↩
  8. Inoue Y, Fujii S, Shinoda K, et al. Subretinal transplantation of bone marrow mesenchymal stem cells delays retinal degeneration in the RCS rat model of retinal degeneration. Experimental Eye Research. 2007;85(2):234-241. doi:10.1016/j.exer.2007.04.007 ↩
  9. Zhang Y, Wang W. Effects of bone marrow mesenchymal stem cell transplantation on light-damaged retina. Investigative Ophthalmology & Visual Science. 2010;51(7):3742-3748. doi:10.1167/iovs.09-4114 ↩
  10. Guan Y, Cui L, Qu Z, et al. Subretinal transplantation of rat MSCs and erythropoietin gene-modified rat MSCs for protecting and rescuing degenerative retina in rats. Current Molecular Medicine. 2013;13(9):1419-1431. doi:10.2174/15665240113139990067 ↩
  11. Park SS, Bauer G, Abedi M, et al. Intravitreal autologous bone marrow CD34⁺ cell therapy for ischemic and degenerative retinal disorders: preliminary phase 1 clinical trial findings. Investigative Ophthalmology & Visual Science. 2014;56(1):81-89. doi:10.1167/iovs.14-15415 ↩
  12. Kahraman NS, Oner A. Umbilical cord-derived mesenchymal stem cell implantation in retinitis pigmentosa: a 12-month follow-up. Stem Cell Investigation. 2018;5:41. doi:10.21037/sci.2018.10.04 ↩
  13. Uyama H, Mandai M, Takahashi M. Stem-cell-based therapies for retinal degenerative diseases: current status and future directions. International Journal of Molecular Sciences. 2022;23(20):12248. doi:10.3390/ijms232012248 ↩
  14. Öner A. Stem cell therapy in retinal diseases: a systematic review. Turkish Journal of Ophthalmology. 2024;54(1):45-55. doi:10.4274/tjo.galenos.2024.87609 ↩
  15. Tzameret A, Sher I, Belkin M, et al. Transplantation of human bone marrow mesenchymal stem cells as a thin subretinal layer enhances photoreceptor survival in Royal College of Surgeons rats. Molecular Vision. 2015;21:650-663. PMC4456685 ↩